Cancer Chemotherapy and Pharmacology

, Volume 18, Supplement 2, pp S34–S39 | Cite as

Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer

  • P. Drings
  • U. Abel
  • H. Bülzebruck
  • P. Stiefel
  • M. Kleckow
  • H. -G. Manke
International Satellite Symposium to the 3rd European Conference on Clinical Oncology Stockholm, June 1985 Recent Experience with Ifosfamide/Mesna in Solid Tumor Ifosfamide, Combination Chemotherapy, Non-small Cell Lung Cancer


In all, 171 patients with histologically verified non-small cell lung carcinoma were treated with ifosfamide 2.0 g/m2 on days 1–5 in combination with (91 patients) etoposide 120 mg/m2 on days 1–3 or (71 patients) with cisplatin 75 mg/m2 on day 1. Therapeutic regimens were repeated after 4 weeks. Supportive treatment with mesna (20% of the ifosfamide doses at 0, 4, and 8 h) was performed. Cisplatin treatment was supported by mannitol-induced diuretic hydration.

The overall response rate of ifosfamide/etoposide was calculated to be 27%, with 1 complete and 24 partial remissions. The median survival time for all patients was 8.5 months, for responders 14 months (P less than 0.05), for patients with no change 9.5 months, and for patients with tumor progression 4 months.

With ifosfamide/cisplatin, there were 4 complete and 21 partial remissions (response rate 35%). The median survival time for all patients was 8.3 months, for responders 11.5 months, and for patients with tumor progression 4 months. Age, sex, and histological tumor type had no significant effect on survival. Patients with better performance stage and limited disease lived significantly longer.

The main side-effects of the cisplatin combination were vomiting, bone marrow depression, and neuropathy. The etoposide combination was tolerated better. Urotoxicity was not significant, as a consequence of treatment with mesna.

The results show that the combination ifosfamide/etoposide or ifosfamide/cisplatin are effective in the treatment of non-small cell lung cancer, being comparable to other combinations of etoposide/cisplatin and vindesine/cisplatin. Because of the better tolerability, the combination ifosfamide/etoposide is superior to cisplatin combinations.


Etoposide Lung Carcinoma Median Survival Time Ifosfamide Partial Remission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Aisner J, Hansen HH (1981) Commentary: current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 65: 979Google Scholar
  2. 2.
    Anderson GT, Peel ET, Cheong CMB, Broderich NJ (1982) Etoposide — an effective single drug for treating bronchogenic carcinoma. Clin Oncol 8: 215Google Scholar
  3. 3.
    Bakowski MT, Crouch JC (1983) Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev 10: 159Google Scholar
  4. 4.
    Britell JA, Eagan RT, Ingle JN, Creagan ET, Rubin J, Frytak S (1979) Cis-dichloramineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versuscis-dichlorodiamine-platinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 63: 29Google Scholar
  5. 5.
    Bhuchar VK, Lanzotti VJ (1982) High-dose cisplatin for lung cancer. Cancer Treat Rep 66: 375Google Scholar
  6. 6.
    Casper ES, Gralla RK, Kelsen DP, Cvitkovic E, Golbey RB (1979) Phase II study of high-dosecis-dichlorodiamineplatinum(II) in the treatment of non-small cell lung cancer. Cancer Treat Rep 63: 2107Google Scholar
  7. 7.
    Chapman R, Itri L, Gralla R, Kelsen D, Casper E, Golbey R (1982) Phase II trial of VP 16-213 in non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol 7: 205Google Scholar
  8. 8.
    Costanzi BJ, Morgan LR, Hokanson J (1982) Ifosfamide in the treatment of extensive non-oat-cell carcinoma of the lung. Semin Oncol 9: 61Google Scholar
  9. 9.
    De Jager R, Longeval E, Klastersky J (1980) High-dose cisplatin with fluid and mannitol-induces diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium). Cancer Treat Rep 64: 1341Google Scholar
  10. 10.
    Drings P (1986) Chemotherapie des nicht-kleinzelligen Bronchialkarzinoms. In: Das Bronchialkarzinom: Biologie, Diagnostik und Therapie. Aktuelle Onkologie 26. Zuckschwerdt p 293Google Scholar
  11. 11.
    Drings P, Stiefel P, Dirks HP, Grimm V, Kleckow M, Manke HG, Queißer W, Abel U, Heinrich S (1984) Chemotherapie des nicht-kleinzelligen Karzinoms der Lunge mit Ifosfamid und Cisplatin. Dtsch Med Wochenschr 109: 3Google Scholar
  12. 12.
    Eagan RT, Frytak S, Creagan RT, Ingle JN, Kvols LK, Carr DT, Coles DT, O'Fallin JR (1977) Platinum-based polychemotherapy versus dianhydrogalactylol in advanced non-small cell lung cancer. Cancer Treat Rep 61: 1339Google Scholar
  13. 13.
    Eagan RT, Ingle JN, Creagan ET, Frytak S, Kvols LK, Rubin J, McMahon RT (1978) VP 16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 62: 843Google Scholar
  14. 14.
    Eagan RT, Frytak S, Creagan RT, Ingle JN, Kvols LK, Coles DT (1979) Phase II study of cyclophosphamide, adriamycin, andcis-dichlorodiamineplatinum(II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 63: 1589Google Scholar
  15. 15.
    Goldhirsch A, Joss R, Cavalli F, Brunner KW (1981) Etoposid-Mono-und Polychemotherapie des Bronchialkarzinoms. In: Seeber S, Nagel GA, Achterrath W, Schmidt CG, Raettig R (eds) Etoposid. Derzeitiger Stand und neue Entwicklung in der Chemotherapie maligner Neoplasien. Zuckschwerdt, p 51Google Scholar
  16. 16.
    Gonzales-Vitale JC, Hayes DM, Cvitikovic E, Sternberg SS (1977) The renal pathology in clinical trials of cisplatinum(II) diaminedichloride. Cancer 39: 1362Google Scholar
  17. 17.
    Gralla RJ, Casper ES, Kelsen DP (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95: 414Google Scholar
  18. 18.
    Hyde L, Yee J, Wilson R, Patno ME (1985) Cell type and the natural history of lung cancer. J Am Med Assoc 193: 140Google Scholar
  19. 19.
    Issel BF, Valdivieso M, Bodey GP (1978) Chemotherapy for adenocarcinoma and large cell anaplastic carcinoma of the lung with ftorafur, adriamycin, and cis-dichlorodiamineplatinum(II). Cancer Treat Rep 62: 1089Google Scholar
  20. 20.
    Joss JA, Brunner KW (1985) Die Chemotherapie der nichtkleinzelligen Bronchialkarzinome. In: Interdisziplinäre Therapie des Bronchialkarzinoms. Springer, Berlin Heidelberg New York Tokyo, p 75Google Scholar
  21. 21.
    Livingston RB (1977) Combination chemotherapy of bronchogenic carcinoma. I non oat cell. Cancer Treat Rev 5: 153Google Scholar
  22. 22.
    Muffia FM, Blum RH, Foreman JD (1984) Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologies. Int J Radiat Oncol Biol Phys 10: 137Google Scholar
  23. 23.
    Panettiere FJ (1980) Effects of the two-dose SWOGcis-platinum (CACP) program in non-oat-cell lung cancer. Proc AACR/ASCO 21: 450, ASVO Abstr C-517Google Scholar
  24. 24.
    Rozenczweig M, von Hoff DD, Slavik M, Muggia FM (1977)cis-Diaminechlorplatinum(II). A new anticancer drug. Ann Intern Med 86: 803Google Scholar
  25. 25.
    Saiers JH, Slavik M (1982) Phase II clinical studies of vindesine and combination of ifosfamide and acetylcysteine in non-small cell lung cancer. Abstract IIIrd World Conference on Lung Cancer, Tokyo, May 17–20, Abstr 174, p 132Google Scholar
  26. 26.
    Sculier JP, Klastersky J (1984) Progress in chemotherapy of non-small cell lung cancer. Eur J Cancer Clin Oncol 20: 1329Google Scholar
  27. 27.
    Seeber S, Higi M (1980) Zur kombinierten Chemotherapie des nicht-kleinzelligen Bronchialkarzinoms. In: Seeber S, Schmidt G, Nagel G, Achterrath W (eds) Cisplatin-derzeitiger Stand und neue Entwicklung in der Chemotherapie maligner Neoplasien. Karger, Basel, p 163Google Scholar
  28. 28.
    Senn HJ (1979) Chemotherapeutische Möglichkeiten bei Bronchialkarzinomen. Therapiewoche 29: 8784Google Scholar
  29. 29.
    Sonntag RW (1979)Cis-Diaminedichloroplatin(II). Eine neue Art von Zytostatikum. Onkologie 2: 129Google Scholar
  30. 30.
    Takita H, Marabelle RC, Edgerton F, Ruzzo D (1979)cis-Dichlorodiamineplatinum(II), adriamycin, cyclophosphamide, CCNU, and vincristine in non-small cell carcinoma: a preliminary report. Cancer Treat Rep 36: 29Google Scholar
  31. 31.
    Varini M, Piquet D, Beer M, Piazza E, Cattaneo MT, Brambilla-Pisoni M (1981) Ifosfamide (IF) with the uroprotective agent mesna (MS) in the treatment of squamous cell carcinoma of the lung. 17th International Congress of Chemotherapy, Florence, Abstr 174, p 85Google Scholar
  32. 32.
    Vogl SE, Berenzweig M, Camacho F, Greenwald E, Kaplan BH (1982) Efficacy study of intensivecis-platin therapy in advanced non-small cell bronchogenic carcinoma. Cancer 50: 24Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • P. Drings
    • 1
  • U. Abel
    • 2
  • H. Bülzebruck
    • 1
  • P. Stiefel
    • 1
  • M. Kleckow
    • 1
  • H. -G. Manke
    • 1
  1. 1.Department of Medical OncologyRohrbach Chest HospitalHeidelbergGermany
  2. 2.German Cancer Research CenterHeidelbergGermany

Personalised recommendations